Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLADIATOR: Geranylgeranylacetone in HFpEF
NCT05672134Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of teprenone in heart failure with preserved ejection fraction (HFpEF), sponsored by Amsterdam University Medical Center. Started Apr 2023; status: completed.
02
Drugs
teprenone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05672134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672134.